Inhalation Drug Delivery Market - Strategic Insights and Forecasts (2026-2031)

The Inhalation Drug Delivery Market is forecast to grow significantly, from USD 44.1 billion in 2026 to USD 59.1 billion by 2031. This represents a compound annual growth rate (CAGR) of 6.01%, driven by sustained demand for maintenance therapies for chronic respiratory conditions.

Innovation in the market is being driven by advanced device technologies such as dry powder inhalers (DPIs), soft mist inhalers (SMIs), and digital smart inhalers, which offer improved drug deposition and adherence monitoring. Therapeutically, the focus is shifting towards anti-inflammatory therapies, combination inhalers, and the approval of ultra-long-acting biologics like depemokimab for severe asthma.

Environmental regulatory mandates are a key driver, specifically the EU F-gas Regulation (2024/573) and the U.S. AIM Act. These regulations, which removed quota exemptions for metered-dose inhalers (MDIs) as of January 2025, are compelling manufacturers to transition from high-global-warming-potential propellants like HFA-134a to lower-GWP alternatives such as HFA-152a and HFO-1234ze to meet environmental compliance.

Pharmaceutical companies are actively realigning their supply chain strategies by adjusting production and forming partnerships to mitigate risks associated with raw material availability. This includes capacity expansions in regions such as the United Kingdom and China, demonstrating efforts to secure capabilities for low-carbon inhaler production in response to new environmental mandates.

The scope of inhalation therapies is expanding beyond traditional asthma and COPD treatments into specialized respiratory diseases. Recent approvals, such as nerandomilast (Jascayd) for idiopathic pulmonary fibrosis (IPF), highlight a growing focus on addressing a broader range of complex conditions via inhalation drug delivery, broadening the clinical applications of the market.

The primary market drivers include the increasing prevalence of chronic respiratory diseases like COPD, asthma, and interstitial lung diseases, exacerbated by environmental pollution and aging demographics globally. Additionally, clinical guideline updates emphasizing combination and anti-inflammatory therapies over short-acting bronchodilators are redirecting demand towards long-acting maintenance devices and advanced therapeutic regimens.